T2D and CV Risk Reduction: Future Management

June 12, 2019 12:51 pm

Future considerations for managing patients with type 2 diabetes and associated cardiovascular risk based on emerging data and clinical recommendations with SGLT2 inhibitors and GLP-1 agonists.

Category: News
About The Author
-
Previous

Hua Medicine – A Global Effort to Stop Diabetes
Next

EASD 2019 : Personalised Prevention Of CVD In T2D- Prof Alessandro Doria

Related Videos

Unleashing-the-Truth-How-to-Put-T2D-Patients-Hearts-First

Unleashing the Truth: How to Put T2D Patients’ Hearts First

Preview-A-low-carb-diet-for-T2D-reversal-Dr.-Sarah-Hallberg

[Preview] A low-carb diet for T2D reversal – Dr. Sarah Hallberg

Type-2-Diabetes-Dr-Hull-The-Focus-of-Treatment-in-T2D

Type 2 Diabetes: Dr Hull – The Focus of Treatment in T2D

Zanetti-et-al-Birthweight-T2D-and-Cardiovascular-Disease

Zanetti et al; Birthweight, T2D, and Cardiovascular Disease

Type-2-Diabetes-Treatments-1

A Data Integration Multi-Omics Approach to Study Calorie Restriction-Induced Changes in Insulin Sensitivity

Type-2-Diabetes-Dr-Stephen-Hull-Practical-Advice-for-People-with-T2D-and-Heart-Disease

Type 2 Diabetes: Dr Stephen Hull – Practical Advice for People with T2D and Heart Disease